Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies – A population-based study from northern Sweden

References

• Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003;30:110–15.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, et al. Characterization of familial Waldenstrom’s macroglobulinemia. Ann Oncol 2006;17:488–94.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: A population-based study in Sweden. Blood 2008;112:3052–6.
   PubMed Web of Science ®Google Scholar
• Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood 2008;111:4029–38.
   PubMed Web of Science ®Google Scholar
• Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A, et al. Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:87–97.
   PubMedGoogle Scholar
• Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia. Arch Intern Med 2008;168:1903–9.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Koshiol J, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 2010;102:557–67.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders – what are the driving forces? Semin Cancer Biol 2014;24:61–70.
   PubMed Web of Science ®Google Scholar
• Schöllkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885–90.
   PubMed Web of Science ®Google Scholar
• Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: A population-based study. AIDS 2014;28:2313–18.
   PubMedGoogle Scholar
• Massari R, Fine JM, Metais R. Waldenstrom’s macroglobulinaemia observed in two brothers. Nature 1962;196:176–8.
   PubMed Web of Science ®Google Scholar
• McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S, et al. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res 2007;13:5063–9.
   PubMed Web of Science ®Google Scholar
• McMaster ML. Familial Waldenstrom’s macroglobulinemia. Semin Oncol 2003;30:146–52.
   PubMed Web of Science ®Google Scholar
• Linet MS, Humphrey RL, Mehl ES, Brown LM, Pottern LM, Bias WB, et al. A case-control and family study of Waldenstrom’s macroglobulinemia. Leukemia 1993;7:1363–9.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. Cancer 2012;118:3793–800.
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y, et al. Incidence of lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996–2003. Int J Cancer 2014;134:174–80.
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Jack RH, Davies E, Moller H, Schey SA, South Thames Haematology Specialist Committee. The incidence and survival of Waldenstrom’s Macroglobulinaemia in South East England. Leuk Res 2008;32:55–9.
   PubMed Web of Science ®Google Scholar
• Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003. Int J Cancer 2007;121:2260–6.
   PubMed Web of Science ®Google Scholar
• Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 2010;102:1336–43.
   PubMed Web of Science ®Google Scholar
• Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: A population-based study of 12 482 persons from the national health and nutritional examination survey. Leukemia 2014;28:1537–42.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9.
   PubMed Web of Science ®Google Scholar
• McMaster ML, Landgren O. Prevalence, clinical aspects, and natural history of IgM MGUS. Cytometry B Clin Cytom 2010;78(Suppl 1):S91–7.
   Google Scholar
• Ogmundsdottir HM, Einarsdottir HK, Steingrimsdottir H, Haraldsdottir V. Familial predisposition to monoclonal gammopathy of unknown significance, Waldenstrom’s macroglobulinemia, and multiple myeloma. Clin Lymphoma Myeloma 2009;9:27–9.
   PubMedGoogle Scholar
• Kyle RA, Dispenzieri A, Kumar S, Larson D, Therneau T, Rajkumar SV. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom’s macroglobulinemia (SWM). Clin Lymphoma Myeloma Leuk 2011;11:74–6.
   PubMed Web of Science ®Google Scholar
• McMaster ML, Kristinsson SY, Turesson I, Bjorkholm M, Landgren O. Novel aspects pertaining to the relationship of Waldenstrom’s macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia. Clin Lymphoma Myeloma 2009;9:19–22.
   PubMedGoogle Scholar